PHASE Scientific Announces CE Mark Approval for the PHASIFY VIRAL RNA Extraction Kit

B2B Training: What’s the Most Effective Way of Learning?

B2B training, which is short for business-to-business training, is a popular and convenient type of training that enables entire companies to train their teams...

AlixPartners Forecasts: Household Products Could Cost U.S. Manufacturers and Consumers 15% More This Year Due to Resin Shortage

While companies can’t control the market forces at play, they can take action to mitigate the risk and impact of supply chain disruption.

July 20, 2020

PHASE Scientific, a fast-growing biotechnology company, announced it has received the Conformité Européene (CE) Mark approval for its PHASIFY VIRAL RNA Extraction Kit.

PHASE Scientific notes the CE marking confirms that PHASIFY VIRAL complies with the European In-Vitro Diagnostic Devices Directive (98/79/EC), which enables PHASE Scientific to expand commercialization of PHASIFY VIRAL to the European Union and other CE Mark geographies as part of the fight against COVID-19.

The PHASIFY VIRAL RNA Extraction Kit is designed to purify and concentrate viral RNA in patient viral transport media samples, and is intended as part of global efforts in detecting and controlling the COVID-19 disease. Attested by the company, PHASIFY VIRAL improves input sample quality, enabling earlier detection, improved overall sensitivity and bolsters confidence in COVID-19 diagnostic test results.

According to Jeffrey D, Klausner, Ph.D., Principal Investigator at the National Institutes of Health (US) and Professor of Medicine and Public Health at UCLA, input sample quality is a major bottleneck in COVID-19 detection accuracy, “unfortunately, as only miniscule amounts of viral RNA exist in patient samples, most conventional viral RNA extraction kits encounter constraints in both sample input volume and final elution volume, which results in only 1-2% of the total viral RNA available for analyses. That suggests the current viral RNA extraction kits play a major role in limiting analytic sensitivity.”

“Utilizing PHASIFY VIRAL RNA extraction can result in 15-30-fold greater amount of viral RNA for standard RT-qPCR analyses,” says Klausner. “The increased sample quality can improve analytic sensitivity and reduce false negative results.”

The PHASIFY VIRAL product can facilitate greater SARS-CoV-2 RNA yields. According to the company, in-house and clinical validation data have shown PHASIFY VIRAL can enable a 3-6 cycle threshold reduction compared to solid phase extraction. Clinical studies have also shown PHASIFY VIRAL increases true positive detection compared to conventional solid phase extraction.

This capability is realized through PHASE Scientific’s proprietary technology PHASIFY, which has the ability to isolate and concentrate target molecules, making them easier to detect. Incorporating the technology can make diagnostic tests more affordable, accessible, faster, easier, and more accurate.

Additional advantages of PHASIFY VIRAL RNA Extraction Kit include the ability to increase the sample input volume up to 600µL per extraction and enhance final viral RNA concentration with flexible elution volumes down to 10µL. Its easy-to-use design requires no additional specialized equipment such as magnetic racks and vacuum pumps for operation.

PHASE Scientific has developed an array of products to combat COVID-19, which includes antibody rapid tests, sample preparation kits, and RT-qPCR kits.

“PHASIFY VIRAL, as part of our many contributions for containing the global pandemic, marks a new step forward for both the company and our global collaborators in detecting and controlling the COVID-19 disease,” says PHASE Scientific Founder and CEO Ricky Chiu, Ph.D. “Akin to other countries, we are confident our entry into the European market can benefit both healthcare providers and patients in the region to accelerate the return of healthier communities and the re-opening of global economies.”



Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.